| Asthma |
2014-005611-16: Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation after Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients |
|
|
| Ongoing | 4 | 60 | Europe | Human C1-inhibitor, Powder and solvent for solution for infusion, Capsule, Film-coated tablet, Coated tablet, Cinryze, Vancocin, Ciprofloxacine Actavis, Metronidazol | Academic Medical Center, University of Amsterdam, Academic Medical Center, University of Amsterdam | Mild asthmatics with house dust mite allergy, Mild asthmatics with house dust mite allergy, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2015-004455-52: An open 4-week study to evaluate the efficacy and safety of Serroflo ® comparing with Viani ® in patients with stable persistent asthma Eine offene 4-Wöchige klinische Studie zur Bestimmung der Sicherheit und Wirksamkeit von Serroflo® im Vergleich zu Viani® bei Patienten mit stabilem anhaltendem Asthma |
|
|
| Ongoing | 4 | 220 | Europe | Pressurised inhalation, suspension, SERROFLO 25 Mikrogramm / 125 Mikrogramm / Dosis Druckgasinhalation, Suspension, Viani Dosier-Aerosol 25 μ g/125 μ g Druckgasinhalation, Suspension | Cipla Europe NV, Cipla Europe NV | Asthma, Asthma Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Ongoing | 4 | 24 | Europe | Singulair, Coated tablet, Singulair | Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University Salzburg, Paracelsus Medical University Salzburg | Montelukast is indicated for prophylaxis and chronic treatment of asthma and for the relief of symptoms of seasonal allergic rhinitis.We investigate side effects of Montelukast, specifically potential effects on brain activity., Montelukast is used for treatment of asthma and allergic rhinitis. We examine the effect of Montelukast on brain activity., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Ongoing | 4 | 900 | Europe | Fluticasone Furoate, Inhalation powder | GlaxoSmithKline Research & Development Limited, GlaxoSmithKline Research & Development Limited | Paediatric Subjects with Asthma, Paediatric Subjects with Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2015-001736-38: The utility of feNO in the differential diagnosis of chronic cough |
|
|
| Not yet recruiting | 4 | 60 | Europe | Montelukast, Prednisolone, Film-coated tablet, Tablet, Montelukast, Prednisolone | Hull and East Yorkshire Hospitals NHS trust, Aerocrine Limited | Chronic cough is a common and poorly diagnosed condition. Younger patients tend to receive a diagnosis of asthma, whereas older patients are increasingly identified has having gastroesophageal reflux disease. Those patients presenting with upper airway symptoms are frequently labelled as having rhinitis. A considerable proportion of patients elude a diagnosis, either through testing or by the use of therapeutic trials and are then labelled as idiopathic cough., Chronic cough is a common and poorly diagnosed condition. There are different causes of chronic cough the most common causes are asthma, postnasal drip and gastro-oesophageal reflux., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2017-000735-14: A study comparing whether the new drug comprising fluticasone propionate and salmeterol doses of 125μg and 25μg HFA MDI inhaler (spray pressure) applied two puffs twice daily is not less effective than the dose of 500μg / 50μg applied one puff twice daily as powder inhaler (DPI) in patients with asthma Badanie porównujące czy nowy lek zawierający propionian flutikazonu I salmeterol w dawkach 125µg i 25µg w inhalatorze MDI HFA (aerozol ciśnieniowy) dwa wziewy dwa razy dziennie jest nie mniej skuteczny niż lek referencyjny w dawce 500µg/50µg jeden wziew dwa razy dziennie w inhalatorze proszkowym (DPI) u pacjentów z astmą oskrzelową |
|
|
| Ongoing | 4 | 220 | Europe | Inhalation solution, Inhalation powder, COMBOTEROL fluticasone propionate/salmeterol (125μg / 25μg) in MDI HFA inhaler, Seretide Disc 500 fluticasone propionate/salmeterol (500μg / 50μg) in DPI device | Lek-Am Sp. z o.o., Lek-Am Sp. z o.o. | Asthma is a common, chronic respiratory disease affecting 1–18% of the population in different countries. Asthma is characterized by variable symptoms of wheeze, shortness of breath, chest tightness and/or cough, and by variable expiratory airflow limitation. Both symptoms and airflow limitation characteristically vary over time and in intensity. These variations are often triggered by factors such as exercise, allergen or irritant exposure, change in weather, or viral respiratory infections. Astma to heterogenna choroba, zwykle związana z przewlekłym zapaleniem dróg oddechowych, zdefiniowana przez zespół objawów ze strony układu oddechowego jak świsty, duszności, ucisk w klatce piersiowej i kaszel, zmieniających się w czasie i o różnym nasileniu, którym towarzyszy zmienna obturacja dróg oddechowych, Asthma is a common condition that affects the airways. The typical symptoms are wheeze, cough, chest tightness, and shortness of breath. Symptoms can range from mild to severe. Astma jest przedwlekłą chorobą dróg oddechowych. Typowe objawy to świszczący oddech, kaszel, ucisk w klatce piersiowej i duszność. Objawy mogą się wahać od łagodnych do bardzo ciężkich.., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-000578-31: Impact of benralizumab treatment on asthma Einfluss einer Benralizumab-Behandlung auf Asthma |
|
|
| Not yet recruiting | 4 | 20 | Europe | Fasenra, Fasenra | University Medicine Rostock, AstraZeneca | Eosinophilic Asthma Eosinophilic asthma, Asthma Asthma, Body processes [G] - Immune system processes [G12] | | | | |
2017-003958-16: Effect of Reslizumab on small airways in asthma. RESSAPEA Effect van Reslizumab op de kleine luchtwegen |
|
|
| Ongoing | 4 | 33 | Europe | Solution for infusion, Cinqaero | Academic Medical Center, University of Amsterdam, Academic Medical Center | 1. Patients with severe eosinophilic asthma Ernstig eosinofiel astma patiënten, Patients with severe eosinophilic asthma Ernstig eosinofiel astma patiënten, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-002591-40: Evaluation of bronchial remodeling during mepolizumab treatment in severe eosinophilic asthma Evaluation du remodelage bronchique lors d’un traitement par mépolizumab dans l’asthme sévère éosinophile |
|
|
| Not yet recruiting | 4 | 40 | Europe | Powder for solution for injection, Nucala | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, LABORATOIRE GLAXOSMITHKLINE | severe oesinophilic asthma asthme sévère éosinophile, severe oesinophilic asthma asthme sévère éosinophile, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-003467-64: A 24-week Study aiming to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using Salbutamol or AntiInflammatory Reliever (SYMBICORT®) as rescue medication in addition to SYMBICORT as daily asthma controller. |
|
|
| Not yet recruiting | 4 | 80 | Europe | Symbicort® Turbohaler® 100 micrograms/6 micrograms/inhalation, Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, Inhalation powder, Symbicort® Turbohaler® | Astra Zeneca AB, Astra Zeneca AB | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Not yet recruiting | 4 | 60 | Europe | Solution for injection, Fasenra (benralizumab) | University Hospital of Montpellier, AstraZeneca | The study population corresponds to severe eosinophilic asthma patients La maladie sur laquelle porte l'étude est l'asthme sévère avec éosinophilie, The study population corresponds to severe eosinophilic asthma patients, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Not yet recruiting | 4 | 150 | Europe | Fasenra, Not applicable, Solution for injection in pre-filled syringe, Solution for injection in pre-filled pen, Fasenra | NHS Greater Glasgow and Clyde, AstraZeneca | Severe Eosinophilic Asthma, Severe asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2016-002014-52: DUAL HOMING MECHANISMS OF EOSINOPHILS TO THE SPUTUM; ONLY ONE OF WHICH IS SENSITIVE FOR MEPOLIZUMAB; The FOOTSTEP study HET EFFECT VAN EEN NIEUW GENEESMIDDEL, NUCALA®, OP HET AFWEERSYSTEEM VAN MENSEN MET ASTMA: DE VOETSTAP STUDIE |
|
|
| Not yet recruiting | 4 | 20 | Europe | Nucala, SB-240563, Nucala | University Medical Center Utrecht, GlaxoSmithKline | severe eosinophilic asthma, Treatment of patients with severe asthma that do not sufficiently respond to current treatment, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2019-003036-23: A study to explore why certain types of inhaled medications cause an increased risk of worse outcomes among asthma patients |
|
|
| Not yet recruiting | 4 | 24 | Europe | Serevent 50 micrograms Accuhaler, Seretide 50/250 micrograms Accuhaler, Atrovent, Inhalation powder, Inhalation solution, Serevent 50 micrograms Accuhaler, Seretide 50/250 micrograms Accuhaler, Atrovent | Imperial College London, European Research Council | Asthma, Asthma (a lung disease in which the tubes in the lungs can become narrowed making it more difficult to breathe comfortably), Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2019-003768-31: Effects of azithromycin treatment on immunesystem in patients with asthma and COPD Effekten af azithromycin behandling på immunsystemet hos patienter med astma og KOL |
|
|
| Ongoing | 4 | 100 | Europe | Azithromycin, J01FA10, Film-coated tablet, Azithromycin | Lungemedicinsk Forskningsenhed, Novo Nordisk Fonden | COPD and asthma, Chronic obstructive pulmonary disease and asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2019-003351-11: Study to the effects of using "triple therapy" on the health status of COPD patients with characteristics of asthma Een onderzoek naar het effect van het gebruik van “triple therapie” op de gezondheids-status van COPD-patiënten met kenmerken van asthma |
|
|
| Not yet recruiting | 4 | 316 | Europe | Trimbow, Pressurised inhalation, Inhalation powder, Trimbow, Anoro or Duaklir Genuair Inhalationpowder or Ultibro Breezhaler or Spiolto Respimat | GPRI, General Practitioners Research Institute (GPRI) | Chronic Obstructive Pulmonary Disease (COPD) patients COPD patiënten, COPD COPD, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2019-004309-28: Study of Clenil® Modulite® at different times of the day in Asthma |
|
|
| Not yet recruiting | 4 | 25 | Europe | Clenil® Modulite® 200 micrograms per actuation pressurised inhalation solution, Pressurised inhalation, solution, Clenil® Modulite® 200 micrograms per actuation pressurised inhalation solution | The Medicines Evaluation Unit (MEU) Ltd. (Investigator led study), JP Moulton Charitable Trust | Mild to moderate atopic asthma, Mild to moderate allergic asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2019-003082-17: How electronic monitoring and feedback affect use of Easyhaler asthma medication. Wie sich elektronische Kontrolle und Rückmeldung auf die Einnahme der Easyhaler-Asthmamedikation auswirken |
|
|
| Not yet recruiting | 4 | 166 | Europe | Inhalation powder, Budesonid Orion Easyhaler 0,2 mg/Dosis, Budesonid Orion Easyhaler 0,4 mg/Dosis, Bufori Easyhaler 160 Mikrogramm/4,5 Mikrogramm, Bufori Easyhaler 320 Mikrogramm/9 Mikrogramm, Flusarion Easyhaler 50 Mikrogramm/250 Mikrogramm, Flusarion Easyhaler 50 Mikrogramm/500 Mikrogramm, Salbu Easyhaler 0,2 mg/Dosis | Orion Corporation Orion Pharma, Orion Corporation Orion Pharma | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2019-004647-74: The effect of dupilumab on lung function and related changes in airway volumes detectable by functional respiratory imaging in patients with moderate-severe asthma |
|
|
| Ongoing | 4 | 340 | Europe | Dupilumab, SAR231893, Solution for injection in pre-filled syringe | Sanofi-Aventis Groupe, SANOFI-AVENTIS GROUPE, Sanofi-Aventis Groupe | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2020-002165-34: Predictive Signature of Benralizumab Response Signature prédictive de la réponse au Benralizumab |
|
|
| Not yet recruiting | 4 | 220 | Europe | Benralizumab, Solution for injection in pre-filled syringe, Fasenra | CHU of Nantes, Ministère de la santé - DGOS, Astra-Zeneca France | Severe asthma Asthme sévère, Severe asthma Asthme sévère, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-000829-27: EVEREST: EValuating trEatment RESponses of dupilumab versus omalizumab in Type 2 patients |
|
|
| Ongoing | 4 | 844 | Europe, RoW | Dupilumab, Omalizumab, SAR231893, Solution for injection in pre-filled syringe, Xolair | Sanofi-aventis Recherche & Développement, Sanofi-aventis Recherche & Développement | Chronic rhinosinusitis with nasal polyps, Chronic rhinosinusitis with nasal polyps, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT04585997: Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab". |
|
|
| Recruiting | 4 | 200 | RoW | Mepolizumab, Nucala, Omalizumab, Xolair | University of Newcastle, Australia, GlaxoSmithKline | Asthma, Eosinophilic Asthma | 06/22 | 12/22 | | |
2019-004676-18: Comparison of the mode of action of two anti-asthma drugs, mepolizumab and benralizumab, during treatment of asthma patients with moderate to severe asthma. Vergelijking van de werkingsmechanismen van twee anti-astma medicijnen, mepolizumab en benralizumab, tijdens de behandeling van patiënten met matig tot ernstig astma. |
|
|
| Not yet recruiting | 4 | 72 | Europe | Nucala, Fasenra, SB-240563, IW-8405, Solution for injection in pre-filled pen, Nucala, Fasenra | University Medical Center Utrecht, GlaxoSmithKline | severe eosinophilic asthma ernstig eosinofiel astma, Treatment of patients with severe asthma that do not sufficiently respond to current treatment Behandeling van patiënten met ernstig asthma die niet goed op huidige therapie responderen, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
SHAMAL, NCT04159519 / 2019-001924-37: A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab |
|
|
| Completed | 4 | 168 | Europe | Symbicort®, budesonide/formoterol, Fasenra®, benralizumab, Ventolin®, salbutamol | AstraZeneca | Asthma, Severe Eosinophilic Asthma | 01/23 | 01/23 | | |
eMOFEE, NCT04869384: Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With Asthma |
|
|
| Recruiting | 4 | 166 | Europe | Reminders and feedback to improve adherence, No reminders and feedback to improve adherence | Orion Corporation, Orion Pharma | Asthma | 04/23 | 04/23 | | |
VESTIGE, NCT04400318 / 2019-004647-74: The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma |
|
|
| Completed | 4 | 109 | Europe, US, RoW | Dupilumab, SAR231893 Dupixent, Placebo | Sanofi, Regeneron Pharmaceuticals | Asthma | 06/23 | 08/23 | | |
NCT05036733: Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma |
|
|
| Completed | 4 | 15 | US | Dupilumab, Dupixent | University of Michigan, Regeneron Pharmaceuticals | Asthma | 06/23 | 06/23 | | |
2021-003951-41: A Study to Test if Using the BF Digihaler System is Effective in Getting Better Control of Asthma in Adult Patients Compared to Usual Care |
|
|
| Not yet recruiting | 4 | 500 | Europe | Budesonide/Formoterol Digihaler Digital System, ICS/LABA combinations, NA, Inhalation powder, Inhalation solution, ICS/LABA combinations | Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-001573-22: Use of Buventol and Bufomix Easyhaler in methacholine challenge andtheir effect on inhalation profiles in experimentally induced asthma attacks Buventol ja Bufomix Easyhalerin käyttö metakoliinialtistuksen avaavana lääkkeenä sekä niiden vaikutus sisäänhengitysprofiileihin kokeellisesti aiheutetussa astmakohtauksessa |
|
|
| Not yet recruiting | 4 | 180 | Europe | Buventol® Easyhaler® 200 µg/dose inhalation powder, Bufomix® Easyhaler® 160/4.5µg/inhalation, inhalation powder, Ventoline® Evohaler® 100 µg/inhalation pMDI, Inhalation powder, Inhalation solution, Buventol® Easyhaler® 200 µg/dose inhalation powder, Bufomix® Easyhaler® 160/4.5µg/inhalation, inhalation powder, Ventoline® Evohaler® 100 µg/inhalation | Orion Corporation, Orion Corporation | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Completed | 4 | 180 | Europe | Buventol® Easyhaler® 200 µg/inhalation dmDPI, Salbutamol 200 µg/dose dmDPI, Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI, Budesonide/formoterol 160/4.5 µg/inhalation dmDPI, Ventoline® Evohaler® 100 µg/inhalation pMDI, Salbutamol 100 µg/dose MDI | Orion Corporation, Orion Pharma | Asthma | 06/23 | 06/23 | | |
| Completed | 4 | 139 | RoW | Benralizumab | AstraZeneca | In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India | 07/23 | 07/23 | | |
| Completed | 4 | 40 | Europe, US | dupilumab, Dupixent®, SAR231893, Matching placebo | Regeneron Pharmaceuticals | Asthma | 07/23 | 07/23 | | |
NCT03694158: Investigating Dupilumab's Effect in Asthma by Genotype |
|
|
| Recruiting | 4 | 150 | US | Dupilumab, Dupixent®, Placebo | Boston Children's Hospital, National Institute of Allergy and Infectious Diseases (NIAID), Regeneron Pharmaceuticals, HealthBeacon Plc, Merck Sharp & Dohme LLC, Sanofi | Asthma | 09/26 | 03/27 | | |
MORPHEO, NCT04502862 / 2020-001217-20: A Phase 4, Randomized, Double-blind, Placebo-controlled,Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma |
|
|
| Completed | 4 | 202 | Europe, Canada, US, RoW | SAR231893, Dupixent, Placebo | Sanofi, Regeneron Pharmaceuticals | Asthma | 10/23 | 11/23 | | |
PRISM, NCT04276233: Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma |
|
|
| Completed | 4 | 100 | RoW | Mepolizumab, Salbutamol | GlaxoSmithKline, Tech Observer | Asthma | 10/23 | 10/23 | | |
| Completed | 4 | 157 | Europe | Benralizumab | NHS Greater Glasgow and Clyde, University of Glasgow, AstraZeneca, Queen's University, Belfast, Bosch Healthcare Solutions GmbH, InHealthcare, University of Leicester, University of Plymouth, Vitalograph | Asthma | 02/24 | 04/24 | | |
| Completed | 4 | 45 | Europe, US, RoW | Benralizumab, Fasenra | AstraZeneca | Asthma | 07/24 | 07/24 | | |
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma |
|
|
| Recruiting | 4 | 1136 | Canada, Japan, US, RoW | Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists | GlaxoSmithKline | Asthma | 03/26 | 03/26 | | |
ANCHOR, NCT06422689: Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care |
|
|
| Recruiting | 4 | 2000 | US | Albuterol and budesonide inhalation aerosol, PT027 | AstraZeneca, Premier HealthCare Solutions Inc. | Asthma | 04/26 | 04/26 | | |
| Recruiting | 4 | 60 | US | Dupilumab Injectable Product, Rhinovirus | University of Virginia, Regeneron Pharmaceuticals | Asthma | 05/25 | 01/26 | | |
| Completed | 4 | 1500 | RoW | QIP intervention | AstraZeneca | Asthma | 09/24 | 09/24 | | |
| Active, not recruiting | 4 | 320 | Europe | Administration via pressurized metered dose inhaler (pMDI) | Chiesi Farmaceutici S.p.A. | Asthma | 04/24 | 04/24 | | |
NCT06556264: Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps |
|
|
| Not yet recruiting | 4 | 60 | NA | Dupilumab, dupixent, Placebo | Dr. Andrew Thamboo, MD, Sanofi | Chronic Rhinosinusitis With Nasal Polyps, Asthma | 01/25 | 12/25 | | |
| Completed | 4 | 101 | US | AirDuo Digihaler, ProAir Digihaler | University of Michigan, Teva Branded Pharmaceutical Products R&D, Inc. | Asthma | 12/23 | 12/23 | | |
DARWIN, NCT06563102: Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma |
|
|
| Not yet recruiting | 4 | 100 | US | Albuterol/Budesonide, AIRSUPRA, BDA MDI HFA, Albuterol, AS MDI | AstraZeneca, Fortrea | Mild Asthma | 11/25 | 11/25 | | |
AIM4:Next Step, NCT06572228: Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma |
|
|
| Not yet recruiting | 4 | 250 | NA | dupilumab, Dupixent®, REGN668, SAR231893, Matching Placebo, ICS/LABA, fluticasone, propionate/salmeterol HFA, inhalation aerosol | Regeneron Pharmaceuticals, Sanofi | Asthma | 12/26 | 12/26 | | |
| Active, not recruiting | 4 | 320 | Europe, Canada, US, RoW | Dupilumab, SAR231893 Dupixent, Omalizumab, Xolair, Placebo | Sanofi, Regeneron Pharmaceuticals | Chronic Rhinosinusitis With Nasal Polyps, Asthma | 10/24 | 01/25 | | |
NCT05097287 / 2021-003903-16: Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma |
|
|
| Recruiting | 4 | 1324 | Europe, Canada, US, RoW | Dupilumab, Placebo | Sanofi, Regeneron Pharmaceuticals | Asthma | 10/29 | 01/30 | | |
PASSAGE, NCT05329194: Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States |
|
|
| Recruiting | 4 | 400 | US | Tezepelumab, AMG 157 or MEDI9929 | AstraZeneca, Parexel | Asthma | 07/25 | 07/25 | | |
SECURE, NCT05626777: Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices |
|
|
| Recruiting | 4 | 130 | Europe | Pre-filled syringe, mepolizumab 100 mg/month, Auto-injector pen, mepolizumab 100 mg/month | Hospices Civils de Lyon, GlaxoSmithKline | Asthma | 03/26 | 07/26 | | |
REIMAGINE, NCT06041386: - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study |
|
|
| Not yet recruiting | 4 | 336 | NA | Mepolizumab, NUCALA, Spirometry | GlaxoSmithKline | Asthma | 07/26 | 07/26 | | |
| Recruiting | 4 | 81 | Europe, Canada, US | Benralizumab, Placebo | AstraZeneca | Asthma | 09/26 | 09/26 | | |
| Recruiting | 4 | 220 | Europe | Benralizumab Prefilled Syringe, Transcriptomic | Nantes University Hospital, AstraZeneca, Ministère de la Santé - France | Asthma; Eosinophilic, Severe Asthma | 10/26 | 11/26 | | |
2020-001713-20: Efficacy and safety of budesonide/formoterol versus terbutaline nebulization to treat children having an asthma attack Efficacité et sécurité du budenoside/formoterol par rapport à la terbutaline pour traiter les enfants ayant une crise d'asthme |
|
|
| Not yet recruiting | 3 | 102 | Europe | , Inhalation powder, pre-dispensed, Bricanyl, Symbicort | Centre Hospitalier Intercommunal de Créteil, Astrazeneca | moderate asthma exacerbation exacerbation modérée d'asthme, asthma crisis crise d'asthme, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT00986726: Effect of Temperature Controlled Laminar Airflow (TLA) on Rhinitis |
|
|
| Active, not recruiting | 3 | 14 | Europe | Protexo (Temperature controlled Laminar Airflow (TLA)), Protexo, Placebo TLA | Airsonett AB, Croel AB, Commitum AB | Asthma | 01/10 | 02/10 | | |
2011-005553-31: Study to evaluate the effectiveness of fluticasone furoate/vilanterol delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with existing Asthma maintenace therapy alone in subjects with Asthma. |
|
|
| Ongoing | 3 | 4036 | Europe | Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate/GW642444 Inhalation Powder, Inhalation powder, pre-dispensed, Relvar Ellipta | GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, Research and Development Ltd | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2015-004959-50: HELIOX-DRIVEN BETA2-AGONISTS NEBULIZATION FOR CHILDREN WITH MODERATE TO SEVERE ACUTE ASTHMA: A RANDOMIZED CONTROLLED TRIAL HELIOX COMO VEHÍCULO EN LA NEBULIZACIÓN DE BETA 2-AGONISTAS EN NIÑOS CON ASMA AGUDO MODERADO-SEVERO: ENSAYO CLÍNICO CONTROLADO ALEATORIZADO |
|
|
| Ongoing | 3 | 58 | Europe | Heliox (Helium 22% Oxygen 78%), Aire Sintético Medicinal, Medicinal gas, compressed, Aire Medicinal Sintético Carburos Metálicos, 22% v/v gas medicinal, comprimido | S.E. Carburos Metálicos S.A. grupo Air Products, S.E. Carburos Metálicos S.A. grupo Air Products | Moderate to severe exacerbations of asthma EXACERVACION DE ASMA AGUDO DE MODERADO A GRAVE, Moderate to severe exacerbations of asthma EXACERVACION DE ASMA AGUDO DE MODERADO A GRAVE, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2015-002384-42: Randomised Controlled Trial of the efficacy and safety of an ICS (Inhaled Corticosteroid)/LABA (long-acting beta agonist) reliever therapy regimen in asthma. |
|
|
| Ongoing | 3 | 675 | Europe | Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin® Evohaler® 100 micrograms, N/A, Inhalation powder, Pressurised inhalation, Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin Inh. CFC free 100 micrograms | Medical Research Institute of New Zealand, Astra Zeneca | Asthma., Asthma., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2014-002659-25: An Open-Label Safety Study of Patients with Severe Eosinophilic Asthma Who Were Previously Enrolled in the Reslizumab Open Label Extension Study C38072/3085 |
|
|
| Not yet recruiting | 3 | 10 | Europe | Reslizumab, CEP-38072, Concentrate for solution for infusion | Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc. | Treatment for patients with eosinophilic asthma, A particular form of asthma characterized by the presence of a high number in the lungs of a certain type of white blood cells, called eosinophils, which lead to airways inflammation and symptoms., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2017-001532-19: An open-label study to compare the effectiveness of FF/UMEC/VI using the Connected Inhaler System with FP/SAL plus tiotropium in participants with inadequately controlled asthma |
|
|
| Not yet recruiting | 3 | 1006 | Europe | Fluticasone Furoate/Umeclidinium/Vilanterol, (Seretide Accuhaler/DISKUS), Spiriva Respimat, GW685698/GSK573719/GW642444, R03AK06, Inhalation powder, pre-dispensed, Inhalation solution, Trelegy Ellipta, Seretide Accuhaler/Diskus, 250/50 mcg or 500/50mcg, Spiriva Respimat | GlaxoSmithKline Research & Development Ltd, GSK | Inadequately controlled asthma, Inadequately controlled asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-002596-18: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS Birch tablets for patients with tree pollen-induced allergic rhinoconjunctivitis with or without mild controlled asthma Efficacia e sicurezza dell’immunoterapia sublinguale con compresse di Allergoide LAIS Birch per pazienti con rinocongiuntivite allergica indotta da polline d’albero in presenza o assenza di asma lieve controllato |
|
|
| Not yet recruiting | 3 | 110 | Europe | Loratadina, Tablet, Eye drops, suspension, Nasal spray, suspension, CLARITYN - 20 COMPRESSE 10 MG, LEVOSTAB - 0.05 % COLLIRIO, SOSPENSIONE 1 FLACONE 4 ML, PREDNISONE DOC GENERICI - "5 MG COMPRESSE" 10 COMPRESSE IN BLISTER PVC-PVDC/ALU, RINOCLENIL - 50 MCG SPRAY NASALE, SOSPENSIONE FLACONE DA 200 EROGAZIONI | LOFARMA S.P.A., Lofarma S.p.A. | Tree pollen-induced allergic rhinoconjunctivitis Rinocongiuntivite allergica indotta da polline degli alberi, Tree pollen-induced allergic rhinoconjunctivitis Rinocongiuntivite allergica indotta da polline degli alberi, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-002498-23: The Role of Benralizumab on airway Remodeling Assessed by HRCT in severe asthma (BREATH Study) Il ruolo del Benralizumab sul rimodellamento delle vie aeree nell'asma grave valutato tramite HRCT (Studio BREATH) |
|
|
| Not yet recruiting | 3 | 20 | Europe | FASENRA, [MEDI-563], Solution for injection | AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO, Astrazeneca | SEVERE ASTHMA ASMA GRAVE, SEVERE ASTHMA ASMA GRAVE, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Recruiting | 3 | 500 | Europe, Canada, US, RoW | Mepolizumab 40mg or 100mg | GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd | Asthma | 12/19 | 12/19 | | |
| Not yet recruiting | 3 | 18 | Europe | Fasenra, Solution for injection, Fasenra | Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside, AstraZeneca UK Limited | Severe Eosinophilic Asthma, Severe Eosinophilic Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2019-004429-26: A multicentre, randomized, open-label, cross-over equivalence study to compare the pharmacodynamic properties, safety, and tolerability of a new combination dry powder of fluticasone propionate and salmeterol (ComboFS) twice daily and the reference product Seretide® Diskus® in patients with asthma |
|
|
| Not yet recruiting | 3 | 200 | Europe | ComboFS 250 mcg/25 mcg, ComboFS 125 mcg/25 mcg, Seretide® Diskus® 500/50 mcg/dose, Seretide® Diskus® 250/50 mcg/dose, Capsule, Inhalation powder, pre-dispensed, Seretide® Diskus® 500/50 mcg/dose, Seretide® Diskus® 250/50 mcg/dose | PRZEDSIEBIORSTWO FARMACEUTYCZNE LEK-AM SPÓŁKA Z OGRANICZONA ODPOWIEDZIALNOSCIA, PRZEDSIEBIORSTWO FARMACEUTYCZNE LEK-AM SPÓŁKA Z OGRANICZONA ODPOWIEDZIALNOSCIA | asthma, asthma, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-001762-14: Anti-inflammatory effects of Glycopyrronium Ontstekingsremmend effect Glycopyrronium |
|
|
| Not yet recruiting | 3 | 28 | Europe | QMF149, QVM149, Inhalation powder | University Medical Center Groningen, Novartis Pharma AG | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-003715-22: Efficacy and Safety Evaluation for the Treatment of asthma and allergic rhinitis/rhinoconjunctivitis Evaluación de la eficacia y seguridad del tratamiento del asma y de la rinitis/rinoconjuntivitis alergica a gramíneas y ácaros de polvo. |
|
|
| Not yet recruiting | 3 | 140 | Europe | MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000), Suspension for injection | Inmunotek, S.L., Inmunotek, S.L. | Mild to moderate asthma and allergic rhinitis / rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and grass pollen. Asma de leve a moderada y rinitis/rinoconjuntivitis alérgica (intermitente o persistente) debida a hipersensibilidad a ácaros de polvo (Dermatophagoides pteronyssinus y/o D. farinae) y polen de gramíneas., Grass and house dust mite allergy (asthma and rhinitis/rhinoconjunctivitis) Alergia frente a gramíneas y ácaros de polvo (asma y rinitis/rinoconjuntivitis), Diseases [C] - Immune System Diseases [C20] | | | | |
2019-002811-25: Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis sensitized to grass and olive pollen Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderada sensibilizados a gramíneas y olivo |
|
|
| Not yet recruiting | 3 | 180 | Europe | MG01-T517 (10.000-10.000), MG01-T517-(30.000-10.000), Solution for injection | Inmunotek, S.L., INMUNOTEK, S.L. | Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and olive pollen Rinitis alérgica / rinoconjuntivitis con o sin asma leve a moderada por sensibilización a pólen de gramineas y olivo, Grasses and olive tree allergy Alergia frente a Gramíneas y Olivo, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-002865-37: Efficacy and Safety Evaluation for the Treatment of Allergy Against Cupressaceae and grasses. Evaluación de la eficacia y seguridad del tratamiento de la alergia a gramíneas y cupresáceas |
|
|
| Not yet recruiting | 3 | 180 | Europe | MG01-T521 (10.000-10.000), MG01-T521 (30.000-10.000), Solution for injection | Inmunotek, S.L., INMUNOTEK, S.L. | Allergic rhinitis / rhinoconjunctivitis with or without mild to moderate asthma due to sensitization to grass and cupressaceae pollen Rinitis alérgica / rinoconjuntivitis con o sin asma leve a moderada por sensibilización a pólen de gramineas y cupresáceas, Grasses and cupressacease allergy Alergia frente a Gramíneas y cupresáceas, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-003674-27: A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007, PT008 and placebo in asthma patients 4 years of age or older (DENALI). |
|
|
| Not yet recruiting | 3 | 1000 | Europe, RoW | Budesonide/Albuterol Sulfate Pressurized Inhalation Suspension (BDA MDI), Albuterol Sulfate Pressurized Inhalation Suspension (AS MDI), Budesonide Pressurized Inhalation Suspension (BD MDI), PT027, PT007, PT008, Pressurised inhalation, suspension | Bond Avillion 2 Development LP, Bond Avillion 2 Development LP | Symptomatic Asthma, Symptomatic Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
ANASSA-PD, NCT04665895 / 2020-002977-84: A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma |
|
|
| Completed | 3 | 451 | Europe | Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals, FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK, FLOVENT, Placebo | Respirent Pharmaceuticals Co Ltd., Becro Ltd. | Asthma | 08/21 | 02/22 | | |
2021-000149-42: A study to compare SYN008 and Xolair for the treatment of chronic urticaria not well controlled by antihistamines |
|
|
| Ongoing | 3 | 480 | Europe | Omalizumab, Xolair, SYN008, Solution for injection in pre-filled syringe, Solution for infusion in pre-filled syringe, Xolair 150 mg solution for injection in pre-filled syringe | Synermore Biologics Co., Ltd, Synermore Biologics Co., Ltd | Chronic spontaneous urticaria (Allergic asthma, Chronic rhinosinusitis with nasal polyps), Asthma, urticaria, Chronic rhinosinusitis, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Not yet recruiting | 3 | 350 | Europe | Beltavac® with polymerized extract from Dermatophagoides, Suspension for injection | Probelte Pharma S.L.U., NA | Allergic rhinitis/ rhinoconjuntivitis associated or not with asthma rinitis/rinoconjuntivitis alérgica asociada o no con asma, House dust mite allergy Alergia a los ácaros del polvo, Diseases [C] - Immune System Diseases [C20] | | | | |
ASTHMAFAST, NCT04705727: Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation |
|
|
| Terminated | 3 | 102 | Europe | Budesonide Formoterol Drug Combination, nebulisation of terbutaline | Centre Hospitalier Intercommunal Creteil, AstraZeneca | Asthma in Children | 09/21 | 06/23 | | |
2021-001449-11: Study with adult asthmatic patients to understand how asthma symptoms are perceived by comparing two inhalers. Studio con pazienti adulti asmatici per capire come vengono percepiti i sintomi dell'asma confrontando due inalatori. |
|
|
| Not yet recruiting | 3 | 75 | Europe | Beclometasone dipropionato e formoterolo fumarato, Beclometasone dipropionato e formoterolo fumarato diidrato, [CHF1535], Pressurised inhalation, solution, FOSTER - 100/6 MICROGRAMMI PER EROGAZIONE SOLUZIONE PRESSURIZZATA PER INALAZIONE | CHIESI FARMACEUTICI S.P.A., Chiesi Farmaceutici S.p.a. | Moderate to severe asthma Asma da moderata a grave, Moderate to severe asthma Asma da moderata a grave, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-000190-81: Tiotropium in preventing preschool asthma (TIPP) Tiotropium zur Vorbeugung von Asthma bei Vorschulkindern |
|
|
| Not yet recruiting | 3 | 204 | Europe | tiotropium bromide inhalation solution, Inhalation solution | Goethe-University Frankfurt, Federal Ministry for Education and Research (BMBF), Boehringer Ingelheim | Severe asthma exacerbations in partial and uncontrolled preschool asthma Schweres Asthma-Exazerbationen bei teil- und unkontrolliertem Asthma im Vorschulalter, Severe preschool asthma Schweres Asthma im Vorschulalter, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-003673-10: A clinical trial to evaluate the efficacy and safety of PT027 compared to PT007 in asthma patients 4 years of age or older (MANDALA). |
|
|
| Not yet recruiting | 3 | 3100 | Europe, RoW | Budesonide/Albuterol Sulfate Pressurized Inhalation Suspension (BDA MDI), Albuterol Sulfate Pressurized Inhalation Suspension (AS MDI), PT027, PT007, Pressurised inhalation, suspension, Ventolin Evohaler® 100 micrograms | Bond Avillion 2 Development LP, Bond Avillion 2 Development LP | Moderate to severe asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT05299385: The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.) |
|
|
| Recruiting | 3 | 100 | RoW | Conventional rehabilition treatment(e.g leaflet) educated by hospital, the conventional rehabilitation treatment, Digital treatment based on Respiratory Rehabilitation Software, Respiratory Rehabilitation Software | Lifesemantics Corp., Asan Medical Center, KangWon National University Hospital, SMG-SNU Boramae Medical Center | Respiratory System Disease, Chronic Obstructive Pulmonary Disease, Asthma Copd, Lung Cancer, Lung Diseases, Pulmonary Rehabilitation, Respiratory Rehabilitation, Home Based Rehabilitation, Mobile Application, Rehabilitation | 03/22 | 06/22 | | |
2022-000615-31: Clinical trial developed at various hospitals where each patient randomly receive in parallel groups either placebo or treatment. Nor patients or investigators will know what the patient it's being given. This clinical trial evaluates efficacy and safety of the immunotherapy with allergen “Cup a 1” (major protein in Cupressus arizónica) in patients with allergic rhinoconjunctivitis with or without asthma sensitized to Cupressaceae pollen Ensayo clínico en varios centros, donde los pacientes reciben en paralelo aleatoriamente el tratamiento o el placebo (control). Ni investigadores ni pacientes sabrán qué tratamiento están recibiendo. El ensayo clínico evalúa eficacia clínica y seguridad de la inmunoterapia con el alérgeno “cup a 1” (proteína mayoritaria de Cupressus arizónica), en pacientes con rinoconjuntivitis alérgica con o sin asma, sensibilizados al polen de las Cupresáceas |
|
|
| Not yet recruiting | 3 | 150 | Europe | Cup a 1 purified and isolated protein, Cup a 1 MOL, Solution for injection in vial | Diater Laboratorio de Diagnósticos y Aplicaciones Terapéuticas, Diater Laboratorio de Diagnósticos y Aplicaciones Terapéuticas | Allergic patients to the Cupressaceae pollen with moderate/severe allergic rhino conjunctivitis with or without controlled asthma Pacientes alérgicos al polen de las Cupresáceas con rinoconjuntivitis alérgica moderada o grave, con o sin asma controlado, Allergic patients to the Cupressaceae pollen with moderate/severe allergic rhino conjunctivitis with or without controlled asthma Pacientes alérgicos al polen de las Cupresáceas con rinoconjuntivitis alérgica moderada o grave, con o sin asma controlado, Diseases [C] - Immune System Diseases [C20] | | | | |
2021-006691-17: A Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteriod Use in Adults with Oral Corticosteriod Dependent Asthma |
|
|
| Not yet recruiting | 3 | 207 | RoW | Tezepelumab via APFS, MEDI9929 anti-TSLP mAb (AMG157), Solution for injection in pre-filled syringe | AstraZeneca AB, AstraZeneca AB, Amgen | Severe Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Ongoing | 3 | 90 | Europe | Tezepelumab, Solution for injection in pre-filled syringe | University Hospital of Montpellier, AstraZeneca | exacerbating asthma, Severe asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT05813470: Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma |
|
|
| Completed | 3 | 256 | RoW | Omalizumab (CinnaGen), Zerafil®, Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland), Xolair® | Cinnagen | Allergic Asthma, Uncontrolled Moderate to Severe | 01/23 | 01/23 | | |
2022-002977-27: This study will evaluate and confirm that a new formulation of Fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals is therapeutically equivalent to the marketed formulation Advair DISKUS® 100/50 mcg inhalation powder/GSK in patients with asthma Aυτή η μελέτη θα αξιολογήσει και τεκμηριώσει ότι ένα νέο σκευάσμα Προπιονικής Φλουτικαζόνης 100mcg και Σαλμετερόλης 50mcg/Respirent Pharmaceuticals κόνις για εισπνοή είναι θεραπευτικά ισοδύναμο του εγκεκριμένου σκευάσματος ADVAIR DISKUS® 100/50mcg κόνις για εισπνοή/GSK σε ασθενείς με άσθμα |
|
|
| Ongoing | 3 | 451 | Europe | Fluticasone propionate 100μg/salmeterol 50μg (as xinafoate) inhalation powder/Respirent, Inhalation powder, pre-dispensed, ADVAIR DISKUS® | Respirent Pharmaceuticals Co. Ltd, Respirent Pharmaceuticals Co. Ltd | Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation Το άσθμα είναι μια ετερογενής ασθένεια, που συνήθως χαρακτηρίζεται από χρόνια φλεγμονή των αεραγωγών. Ορίζεται από ιστορικό αναπνευστικών συμπτωμάτων όπως συριγμός, δυσκολία στην αναπνοή, σφίξιμο στο στήθος και βήχα που μεταβάλλονται στο χρόνο αλλά και σε ένταση, μαζί με μια μεταβλητή απόφραξη των αεραγωγών., Asthma is a chronic inflammatory disease of the airways that is complex and characterized by symptoms as airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation. Το άσθμα είναι μια χρόνια φλεγμονώδης νόσος των αεραγωγών που είναι σύνθετη και χαρακτηρίζεται από συμπτώματα οπως απόφραξη της ροής του αέρα, βρογχική υπεραντιδραστικότητα και υποκείμενη φλεγμονή, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Completed | 3 | 695 | RoW | Benralizumab, Placebo | AstraZeneca | Asthma | 01/23 | 01/23 | | |
|
|
| Completed | 3 | 78 | Europe | Exploratory study on patient's perception of Asthma symptoms | Chiesi Farmaceutici S.p.A. | Asthma | 02/23 | 02/23 | | |
| Completed | 3 | 1460 | Europe, Canada, US, RoW | Sublingual allergy immunotherapy tablet, Acarizax, Odactra, Placebo, Placebo sublingual tablet | ALK-Abelló A/S | Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite | 04/23 | 04/23 | | |
2022-003004-33: Assess the efficacy, safety, & tolerability of oral dexpramipexole in severe eosinophilic asthma |
|
|
| Not yet recruiting | 3 | 1395 | Europe | Dexpramipexole 75mg, Dexpramipexole 150mg, KNS-760704, Film-coated tablet | Areteia Therapeutics, Inc., Areteia Therapeutics, Inc. | Severe Eosinophilic Asthma, Severe Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT04191434: Efficacy and Safety of Flamboyant 125/12 Association in the Treatment of Adults With Moderate Asthma |
|
|
| Recruiting | 3 | 134 | RoW | Flamboyant 125/12, Budesonide/formoterol 200/6, Flamboyant 125/12 Placebo, Budesonide/formoterol 200/6 placebo | EMS | Asthma | 05/23 | 10/23 | | |
2021-003014-39: Efficacy and Safety Evaluation for the Treatment of house dust mite induced allergic asthma and rhinitis/rhinoconjunctivitis Evaluación de la eficacia y seguridad del tratamiento del asma y de la rinitis/rinoconjuntivitis alergica a ácaros de polvo doméstico. |
|
|
| Not yet recruiting | 3 | 400 | Europe | MM09 allergoid-mannan conjugates SC (3.000), MM09 allergoid-mannan conjugates SL (3.000), MM09 allergoid-mannan conjugates SL (9.000), Solution for injection, Sublingual spray, solution | Inmunotek, S.L., Inmunotek, S.L. | Etiological treatment of mild to moderate controlled intermittent or persistent allergic asthma and intermittent or persistent allergic rhinitis / rhinoconjunctivitis Tratamiento etiológico de asma alérgica intermitente o persistente controlada de leve a moderada y rinitis/rinoconjuntivitis alérgica intermitente o persistente, House dust mite induced allergy (asthma and rhinitis/rhinoconjunctivitis) Alergia frente a ácaros de polvo doméstico (asma y rinitis/rinoconjuntivitis), Diseases [C] - Immune System Diseases [C20] | | | | |
NCT02455687: Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial. |
|
|
| Recruiting | 3 | 240 | RoW | Hi-dose iv MgSO4, Nebulized budesonide, Pulmicort, Std-dose iv MgSO4, Nebulized normal saline | Hamad Medical Corporation | Bronchial Asthma | 12/24 | 01/25 | | |
| Not yet recruiting | 3 | 750 | Europe | Dexpramipexole 75mg, Dexpramipexole 150mg, KNS-760704, Film-coated tablet | Areteia Therapeutics, Inc., Areteia Therapeutics, Inc. | Eosinophilic Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT04191447: Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma |
|
|
| Recruiting | 3 | 134 | RoW | Flamboyant 200/12, Budesonide / Formoterol 400/12, Flamboyant 200/12 Placebo, Budesonide / Formoterol 400/12 Placebo | EMS | Asthma | 07/23 | 10/23 | | |
AERO-PD, NCT05664061: Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma |
|
|
| Recruiting | 3 | 451 | Europe | Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals, Test (T), ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK, Refernce (R), Placebo | Respirent Pharmaceuticals Co Ltd., Becro Ltd. | Asthma | 07/23 | 12/23 | | |
NCT05322707: BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient |
|
|
| Completed | 3 | 1485 | US | Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Test product, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol, RLD, Placebo, Placebo for Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg | Cipla Ltd. | Asthma | 08/23 | 08/23 | | |
NCT05850494: Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma |
|
|
| Completed | 3 | 52 | US | HFA MDI, Propellant in MDI, HFO MDI | AstraZeneca | Asthma | 08/23 | 08/23 | | |
2020-000455-12: A randomised, parallel-group, double-blind, placebo-controlled phase III trial assessing the efficacy and safety of 5-grass mix SLIT-drops in adults with grass pollen-induced rhinoconjunctivitis |
|
|
| Not yet recruiting | 3 | 440 | Europe, RoW | 5-grass mix SLIT-drops, Oral solution in single-dose container | ALK-Abelló A/S, ALK-Abelló A/S | Grass pollen-induced allergic rhinoconjunctivitis for two years or more with or without asthma, Grass pollen-induced allergic rhinoconjunctivitis, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04874714: Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis |
|
|
| Terminated | 3 | 18 | Europe | MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000), Placebo subcutaneous | Inmunotek S.L., BioClever 2005 S.L., NTS hub S.L | Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis, House Dust Mite Allergy, Pollen Allergy | 10/23 | 10/23 | | |
NCT04891237: Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen |
|
|
| Recruiting | 3 | 180 | Europe | 10,000 MG01 + 10,000 T517, Grasses and olea 10,000, 30,000 MG01 + 10,000 T517, Grasses and olea, Placebo | Inmunotek S.L. | Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic | 10/25 | 01/26 | | |
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid |
|
|
| Active, not recruiting | 3 | 580 | US | Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP | Chiesi Farmaceutici S.p.A. | Asthma | 11/24 | 02/25 | | |
| Completed | 3 | 395 | Europe, Canada, US, RoW | GSK3511294 (Depemokimab), Placebo | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 11/23 | 11/23 | | |